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A B S T R A C T
Background
Inhaled corticosteroids (ICS) are the cornerstone of asthma maintenance treatment in children. Particularly among parents, there is
concern about the safety of ICS as studies in children have shown reduced growth. Small-particle-size ICS targeting the smaller airways
have improved lung deposition and effective asthma control might be achieved at lower daily doses.
Ciclesonide is a relatively new ICS. This small-particle ICS is a pro-drug that is converted in the airways to an active metabolite and
therefore with potentially less local (throat infection) and systemic (reduced growth) side effects. It can be inhaled once daily, thereby
possibly improving adherence.
Objectives
To assess the efficacy and adverse effects of ciclesonide compared to other ICS in the management of chronic asthma in children.
Search methods
We searched the Cochrane Airways Group Register of trials with pre-defined terms. Additional searches of MEDLINE (via PubMed),
EMBASE and Clinicalstudyresults.org were undertaken. Searches are up to date to 7 November 2012.
Selection criteria
Randomised controlled parallel or cross-over studies were eligible for the review. We included studies comparing ciclesonide with other
corticosteroids both at nominally equivalent doses or lower doses of ciclesonide.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information.
Adverse effects information was collected from the trials.
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Main results
Six studies were included in this review (3256 children, 4 to 17 years of age). Two studies were published as conference abstracts only.
Ciclesonide was compared to budesonide and fluticasone.
Ciclesonide compared to budesonide (dose ratio 1:2): asthma symptoms and adverse effect were similar in both groups. Pooled results
showed no significant difference in children who experience an exacerbation (risk ratio (RR) 2.20, 95% confidence interval (CI) 0.75
to 6.43). Both studies reported that 24-hour urine cortisol levels showed a statistically significant decrease in the budesonide group
compared to the ciclesonide group.
Ciclesonide compared to fluticasone (dose ratio 1:1): no significant differences were found for the outcome asthma symptoms. Pooled
results showed no significant differences in number of patients with exacerbations (RR 1.37, 95% CI 0.58 to 3.21) and data from a
study that could not be pooled in the meta-analysis reported similar numbers of patients with exacerbations in both groups. None
of the studies found a difference in adverse effects. No significant difference was found for 24-hour urine cortisol levels between the
groups (mean difference 0.54 nmol/mmol, 95% CI -5.92 to 7.00).
Ciclesonide versus fluticasone (dose ratio 1:2) was assessed in one study and showed similar results between the two corticosteroids
for asthma symptoms. The number of children with exacerbations was significantly higher in the ciclesonide group (RR 3.57, 95%
CI 1.35 to 9.47). No significant differences were found in adverse effects (RR 0.98, 95% CI 0.81 to 1.14) and 24-hour urine cortisol
levels (mean difference 1.15 nmol/mmol, 95% CI 0.07 to 2.23).
The quality of evidence was judged ’low’ for the outcomes asthma symptoms and adverse events and ’very low’ for the outcome
exacerbations for ciclesonide versus budesonide (dose ratio 1:1). The quality of evidence was graded ’moderate’ for the outcome asthma
symptoms, ’very low’ for the outcome exacerbations and ’low’ for the outcome adverse events for ciclesonide versus fluticasone (dose
ratio 1:1). For ciclesonide versus fluticasone (dose ratio 1:2) the quality was rated ’low’ for the outcome asthma symptoms and ’very
low’ for exacerbations and adverse events (dose ratio 1:2).
Authors’ conclusions
An improvement in asthma symptoms, exacerbations and side effects of ciclesonide versus budesonide and fluticasone could be neither
demonstrated nor refuted and the trade-off between benefits and harms of using ciclesonide instead of budesonide or fluticasone is
unclear. The resource use or costs of different ICS should therefore also be considered in final decision making.
Longer-term superiority trials are needed to identify the usefulness and safety of ciclesonide compared to other ICS. Additionally these
studies should be powered for patient relevant outcomes (exacerbations, asthma symptoms, quality of life and side effects). There is a
need for studies comparing ciclesonide once daily with other ICS twice daily to assess the advantages of ciclesonide being a pro-drug
that can be administered once daily with possibly increased adherence leading to increased control of asthma and fewer side effects.
P L A I N L A N G U A G E S U M M A R Y
Ciclesonide compared to budesonide and fluticasone in the treatment of asthma in children
Asthma is a common disease in childhood. Most children with chronic asthma are treated with inhaled corticosteroids (ICS) to control
airway inflammation and reduce asthma symptoms. Although these drugs are considered to be very safe and effective, not all children
achieve full asthma control and some parents are concerned about the possibility of reduced growth or local side effects such as
hoarseness. The challenge for newer ICS is to achieve improved asthma control with fewer side effects. This could be achieved by small-
particle-size ICS, leading to better lung deposition as they penetrate deeper into the small airways. Therefore, asthma control could be
achieved with lower daily doses and with fewer side effects. In children, particle size of ICS might be even more important because of
their smaller airways.
Ciclesonide is a new small-particle-size ICS. The smaller particle size may make the corticosteroid go deeper into the lungs. Potential
advantages are a lower required dose to achieve asthma control, once daily instead of twice daily dosing, and reduced local (oral thrush)
and systemic (growth suppression) side effects.
We found six studies comparing ciclesonide with either budesonide or fluticasone in 3256 children (aged four to 17 years) with chronic
asthma. After three months of treatment with ciclesonide compared to budesonide or fluticasone, no relevant differences could be
found on asthma symptoms, exacerbations or side effects. Ciclesonide compared to a double dose of fluticasone was assessed in one
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study and no differences were found in asthma symptoms, use of rescue medication and adverse effects. However, children receiving
ciclesonide experienced more asthma exacerbations than children in the fluticasone group.
The results of this review regarding the efficacy and safety of ciclesonide compared to other ICS are not conclusive. Relatively few
studies were found, different inhalers were compared and treatment and follow-up time (12 weeks) was too short for the assessment of
relevant outcomes such as exacerbations and growth retardation. Future studies should pay attention to those aspects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children
Patient or population: pat ients with chronic asthma in children
Settings: all sett ings
Intervention: ciclesonide
Comparison: budesonide (dose rat io 1:2)
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score (scale 0 to 4)
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Number of pat ients
with exacerbat ions
Follow-up: 12 weeks









Number of pat ients
with adverse events
Follow-up: 12 weeks




The data could not be
meta-analysed because
the def init ions of ad-
verse events were too
diverse
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).









































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 In one study the dose of budesonide was much higher than what is commonly prescribed in clinical pract ice.
2 Both studies were sponsored by the manufacturer and at least one of the authors of each study was an employee of the
manufacturer that sponsored the study.
3 The intervent ion period of 12 weeks was too short to expect any major changes in this outcome.











































































































B A C K G R O U N D
Description of the condition
Asthma is the most common chronic disease of childhood with a
prevalence of 8% to 15% (Masoli 2004). It is a chronic inflam-
matory disease affecting the whole airway system, including the
small airways (Hamid 1997). Daily inhaled corticosteroids (ICS)
are the cornerstone of treatment of chronic asthma and in re-
cent guidelines ICS are recommended for all patients except those
withmild, intermittent symptoms (British Thoracic Society 2011;
GINA 2011).
Description of the intervention
ICS reduce inflammation in the lungs by modulating the inflam-
matory response of the lung by binding to the glucocorticoid re-
ceptor and suppressing the expression of pro-inflammatory genes.
With asthmatic inflammation occurring in all airways including
the small airways, the challenge of ICS treatment has now focused
mainly on targeting the small airways (Gelfand 2009; Lahzami
2008). Small-particle drugs (median diameter 1.5 µm) penetrate
better in the small airways and improve total lung deposition
in adults, more so when inhaled with slower inspiratory flows
(Usmani 2005).
Potential adverse drug effects of ICS can be divided into local
(such as oral candidiasis and hoarseness) and systemic (adrenal and
growth suppression) effects. Particularly in children growth is still
a major concern for parents and clinicians. Several longitudinal
studies evaluating the effect of ICS on growth have shown a small
decrease in growth velocity (approximately 1 to 2 cm) during the
first year of treatment (Peters 2006). However, long-term follow-
up studies show no change in final adult height (Brand 2001). A
chronic disease such as asthma may lead to suppressed growth as
children with asthma enter puberty at a later age (Brand 2001).
How the intervention might work
The most widely available ICS are beclomethasone dipropionate
(BDP), budesonide and fluticasone propionate. Chlorofluorocar-
bon-BDP and budesonide are considered equipotent; fluticasone
is considered twice as potent compared to chlorofluorocarbon-
BDP and budesonide. Additionally fluticasone and hydrofluo-
roalkane-BDP are regarded as equipotent to ciclesonide and the
recommended dosage of the Global Initiative for Asthma (GINA),
Global Strategy for Asthma Management and Prevention 2011
guideline, is based on this equipotency (GINA 2011). Almost
all ICS are registered for twice-daily use, except for budesonide,
which is also registered for once-daily use.No consistent significant
or clinically relevant differences in effectiveness among available
ICS have been identified (Adams 2007). One systematic review
comparing ICS with small particles (HFA-BDP) with fluticasone
showed no significant difference on forced expiratory volume in
one second (FEV1) and peak expiratory flow (PEF) at a dose ratio
of 1:1 (Lasserson 2006). There are concerns about adrenal sup-
pression with fluticasone given to children at doses greater than
400 µg/day (Adams 2007; Masoli 2004). Studies reporting on
cases of acute adrenal insufficiency in children are almost invari-
ably in children receiving fluticasone and not beclomethasone or
budesonide (Eijkemans 2011; Todd 2002). In addition, children
receiving fluticasone at half the daily dose of budesonide or be-
clomethasone appear to have a higher risk of pharyngitis (Adams
2007).
Ciclesonide is a relatively new drug with several potential advan-
tages over the currently used ICS. It is inhaled as a pro-drug, which
is converted in the airways to an activemetabolite (des-ciclesonide)
and therefore with potentially less local and systemic side effects.
As both ciclesonide and its active metabolite des-ciclesonide are
highly protein bound (~ 99%), this results in a low proportion of
free, unbound drug in the circulation. The 100-fold greater glu-
cocorticoid receptor binding affinity of des-ciclesonide compared
to ciclesonide may be the explanation for the prolonged local anti-
inflammatory action in the lung and its clinical efficacy with once-
daily dosing. Because of extensive first-pass metabolism, the sys-
temic availability of des-ciclesonide is less than 1%. For a detailed
overview we refer to paper published by Dahl (Dahl 2006). Fur-
thermore, from a pressurised metered dose inhaler (pMDI), ci-
clesonide consists of small particles with a volume median diame-
ter of 1.9 µm (compared to a volume median diameter of 3.5 µm
for fluticasone, 2.8 µm for budesonide and 1.9 µm for HFA-BDP)
(De Vries 2009). Because of smaller particle size and lower plume
velocity, ciclesonide has a better delivery to the small airways and
consequently, effective asthma control could be achieved at lower
daily doses.
Ciclesonide is registered for once-daily use. Mean adherence rates
may decline with increased frequency of dosing and therefore a
once-daily use could lead to better compliance compared to twice-
daily use (Guest 2005; Osterberg 2005; Price 2010). Particularly
in adolescents, adherence to treatment is a major problem. Ci-
clesonide has been approved in Europe for children 12 years of age
and older. The drug is delivered by a metered dose inhaler (MDI)
and registered for use with the AeroChamber Plus® spacer.
Why it is important to do this review
The Cochrane Airways Group decided to split the existing re-
view entitled “Ciclesonide versus other inhaled steroids for chronic
asthma” (Manning 2009) into a review restricted to children and
one restricted to adults. The effect of ciclesonide compared to
placebo is subject of another Cochrane review (Manning 2008).
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O B J E C T I V E S
To assess the efficacy and adverse effects of ciclesonide compared
to other ICS in the management of chronic asthma in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCT) comparing ci-
clesonide with another ICS. We included trials of parallel group
design and cross-over trials with a wash-out period of two weeks
or more. Available unpublished data were considered.
Types of participants
Children (younger than 18 years) with physician-diagnosed
chronic asthma in all settings (general practice, outpatient depart-
ments, emergency departments and hospitalised) were eligible for
inclusion. Trials that included children as well as adults (aged 18
years and older) were included provided that the data on children
were reported separately.
Studies with participants with pulmonary diagnosis other than
asthma were excluded.
Types of interventions
This review includes studies that have compared ciclesonide with
other ICS at equivalent and lower doses of ciclesonide. The inter-
vention period had to be at least four weeks. Concomitant thera-
pies for asthma, such as short-acting beta2-agonists (rescue ther-
apy), theophyllines, long-acting beta2-agonists (salmeterol or for-
moterol), and inhaled anticholinergics were permitted provided
that the dose and type of drug remained stable and were the same
in both groups and was not introduced at the start of the trial
as part of the study protocol. Studies involving anti-leukotrienes
(e.g. singular, accolate), combination inhalers (fluticasone-salme-
terol and budesonide-formoterol) or other airway anti-inflamma-
tory asthma therapy (e.g. cromones) were excluded.
Types of outcome measures
Primary outcomes
1. Asthma symptoms: asthma symptom score and number of
days without symptoms and use of rescue medication.
2. (Severe) asthma exacerbations defined as:
◦ hospital admission;
◦ visit to emergency department;
◦ need for additional course of corticosteroids;
◦ a combination of the above.
3. Adverse effects: oropharyngeal candidiasis, sore throat,
symptoms of hoarseness, growth, lower-leg growth, adrenal
insufficiency, plasma cortisol, urinary cortisol excretion.
Secondary outcomes
1. Quality of life.
2. Compliance.
3. Change in lung function (FEV1, Mid expiratory flow 25-
75%)
4. Airway inflammation assessed by biopsy, lavage or exhaled
nitric oxide (fraction of nitric oxide in exhaled air (FeNO))
Search methods for identification of studies
Electronic searches
We identified from the Cochrane Airways Group (CAG) Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE and
CINAHL, and handsearching of respiratory journals and meeting
abstracts (see Appendix 1 for further details). We searched records
in the Specialised Register coded as ’asthma’ using the following
terms:
ciclesonide* or Alveso* or pregnenedione* or CIC
We searched the CAG trials register from June 2007 up toNovem-
ber 2012. Additional searches in MEDLINE and EMBASE were
undertaken using the strategies in Appendix 2 for articles pub-
lished more recently (2007 to 2012).
Searching other resources
Included and excluded studies of the earlier review that included
adults as well as children (Manning 2009) were checked if data
concerning children were reported separately. Reference lists of all
primary studies and review articles were reviewed for additional
references. The manufacturer of ciclesonide (ALTANA Pharma
and Nycomed) and authors of identified trials were contacted and
asked to identify other published and unpublished studies.
We searched www.clinicalstudyresults.org for trial reports of CIC
(December 2011).
Data collection and analysis
Selection of studies
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Two review authors (NB and BLR) screened the title and abstract
of each citation identified for eligibility. Articles that appeared to
meet the inclusion criteria were retrieved in full text. Published
abstracts of trials and trials published in a language other than
English were also included. Then, based on the full text of the ar-
ticles, NB and BLR independently established whether each study
met the inclusion criteria of the review. Disagreement was solved
by discussion.
Data extraction and management
Two review authors extracted the data from the included studies
independently of each other. We attempted to contact study au-
thors to identify additional papers, confirm data for accuracy and
completeness.
We extracted data concerning the following characteristics of the
included studies: study design; patient characteristics such as age,
gender, asthma severity, inclusion and exclusion criteria, setting;
diagnosis and diagnostic criteria used; characteristics of the inter-
ventions such as ICS type, dose, duration of study, method of de-
livery (MDI with or without spacer, breath actuated inhaler (BAI)
or dry powder inhaler (DPI)); inhalation technique (breath hold
after inhalation from DPI or BAI, inhalation from spacer with
single breath followed by breath hold or tidal breathing) and re-
ported outcome measures.
Assessment of risk of bias in included studies
Risk of bias of the included studies was independently assessed
by two review authors according to the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Disagreement was solved by discussion. The following
items were assessed:
1. adequate sequence generation;
2. allocation concealment;
3. blinding (patient reported/subjective outcomes: asthma
symptoms, adverse effects, quality of life, compliance);
4. blinding (other outcomes);
5. incomplete outcome data addressed (patient reported/
subjective outcomes: asthma symptoms, adverse effects, quality
of life, compliance);
6. incomplete outcome data addressed (other outcomes);
7. free of selective reporting;
8. free of other bias? (e.g. baseline differences).
Measures of treatment effect
A mean difference (MD) and 95% confidence interval (CI) was
calculated for continuous variables measured on identical metrics.
A standardised mean difference (SMD) was used for the contin-
uous variables that addressed the same type of outcome, but were
measured on different scales.
For dichotomous outcomes, we calculated a risk ratio (RR).
Unit of analysis issues
The unit of analysis was the patient.
Dealing with missing data
We contacted the authors of trials in which relevant data or infor-
mation was missing that was needed for data synthesis and analy-
ses.
Assessment of heterogeneity
Heterogeneity was assessed by comparing clinical characteristics of
the included studies such as type of patients (age, gender, asthma
severity, etc.), intervention (dose, inhalation technique, duration,
etc.), comparison and outcome measures. Clinical homogeneity
was discussed by the authors of this review and included experts
in the field. Based on this discussion we decided whether pooling
of results was sensible. Statistical heterogeneity was first assessed
by visual inspection of the forest plots. We also applied the Chi
2 test for homogeneity and we calculated the I2 statistic. To in-
crease the power of the test for homogeneity we used a P < 0.1
for rejecting the null-hypothesis of homogeneity. Interpretation of
the statistical heterogeneity was according to the recommendation
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a) and was as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
When interpreting the results of the test for homogeneity and the
I2 statistic, we took into account the size of the studies that were
included in the meta-analysis.
Assessment of reporting biases
We planned to visually inspect funnel plots to assess reporting bias
if we had been able to combine 10 or more trials in a forest plot.
Data synthesis
We only considered data of clinically homogeneous studies eligi-
ble to be combined. We hypothesised that the individual studies
that evaluated the effect of ciclesonide estimated a common effect
and therefore we chose to combine the results using a fixed-ef-
fect model. If statistical heterogeneity was observed (Chi2: P < 0.1
and I2 > 30%) a sensitivity analysis using a random-effects model
was applied, to determine whether variation between the studies
affected the pooled estimate. Furthermore, evidence of statistical
heterogeneity prompted exploration of factors that can explain
heterogeneity such as clinical or methodological characteristics of
studies.
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Summary of findings table
We created ’Summary of findings’ (SoF) tables for each compar-
ison and primary outcomes. We used GRADE-profiler software
to generate SoF tables that included the Grading of Recommen-
dations Assessment, Development, and Evaluation (GRADE) ap-
proach to assess the overall quality of evidence on relevant (pri-
mary) outcomes (asthma symptoms, exacerbations and adverse ef-
fects) (Schunemann 2011a; Schunemann 2011b). Two review au-
thors (SK and NB) independently graded the body of evidence.
According to GRADE, RCTs start as high-quality evidence. There
are five reasons for downgrading the quality of a body of evidence
for a specific outcome: limitations in design, indirectness of evi-
dence, inconsistency, imprecision of results and high probability
of publication bias. All these items were scored and reasons for
downgrading were explicitly stated. Overall quality of evidence
was graded ’high’, ’moderate’ or ’low’ based on the likelihood of
further research changing our confidence in the estimate of effect.
We resolved discrepancies by consensus among two review authors
(SK and NB).
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses, provided we had sufficient data,
according to age (< six years and≥ six years), asthma severity, dose
of ciclesonide and delivery device (identical or different devices
used for ciclesonide and BDP/budesonide/fluticasone) as well as
inhalation manoeuvre.
Sensitivity analysis
Sensitivity analyses were planned to test the robustness of the re-
sults based on the results of the ’Risk of bias’ assessment, provided
we had sufficient data. We planned to repeat analyses with studies
that scored a low risk of bias for allocation concealment, blinding
(outcome: asthma symptoms, adverse effects, quality of life, com-
pliance) or incomplete follow-up (outcome: asthma symptoms,
adverse effects, quality of life, compliance).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Of the included and excluded studies of the existing Cochrane
review of Manning 2009 three studies met our inclusion criteria
(Pedersen 2006; Vermeulen 2007; von Berg 2007). The updated
search yielded 296 citations and an additional search of the website
www.clinicalstudyresults.org yielded 22 references. After screen-
ing of title and abstracts, the full text of 24 studies was assessed.
Two reports identified by the search of www.clinicalstudy.org were
reports of studies identified in the search of the databases (Agertoft
2010; Pedersen 2009). Of all identified studies, one study pub-
lished in full text (Pedersen 2009) and two studies published as
abstracts (Hiremath 2006; Paunovic 2010) met our inclusion cri-
teria. Therefore, a total of six studies were included into this re-
view. An overview of the selection process is shown in Figure 1.
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Figure 1. Study flow diagram.
10Ciclesonide versus other inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In the previous review, four of the 13 ongoing studies were iden-
tified that potentially met our inclusion criteria. To date, three
studies have been completed. One study was published but did
not separately describe the data of children younger than 18 years
of age (Postma 2011) and one study only including adults was
excluded (van den Berge 2009). One study is awaiting classifi-
cation since no full reports were available of the study data (see
Characteristics of studies awaiting classification table). One study
originally found in the National Research Register record could
not be found in the registers archives, and contact details of the
author were no longer up to date (GIWA 2003). No references
were found to published data of this study and therefore this study
is regarded as obsolete.
To retrieve additional data we contacted all contact authors of the
included studies. Two of them replied and re-directed us to the
pharmaceutical companies involved. We did not get a reply from
the companies on our request for additional data.
Included studies
The characteristics of the six included studies are presented in the
Characteristics of included studies table.
Two studies were described as randomised double-blind parallel
groupdesigns (Hiremath 2006; Paunovic 2010) and four studies as
randomised double-blind double-dummy parallel group designs
(Pedersen 2006; Pedersen2009; Vermeulen2007; vonBerg 2007).
All were designed as non-inferiority studies on lung function.
The six studies randomised 3256 children with asthma and in-
cluded children between the age of 4 and 17 years. One study did
not specify how asthma was diagnosed (von Berg 2007), whereas
the other studies diagnosed asthma according to either the guide-
lines of the American Thoracic Society (ATS) (American Thoracic
Society 1987) or the GINA 2003 classification (Pedersen 2006;
Pedersen 2009; Vermeulen 2007). There was insufficient infor-
mation on how asthma was diagnosed in two studies (Hiremath
2006; Paunovic 2010). The children in the fully published studies
had suffered from asthma for at least six months.
In the six included studies, two different comparisons were as-
sessed. Ciclesonide was compared to budesonide (Vermeulen
2007; von Berg 2007) or fluticasone (Hiremath 2006; Paunovic
2010; Pedersen 2006; Pedersen 2009) (see Table 1). All treatment
periods were 12 weeks and outcomes were measured before and
after the intervention period. The dose and delivery of the inter-
ventions varied between studies (see Table 1). Ciclesonide was de-
livered via MDIs in all studies.
All studies assessed our primary outcome asthma symptoms. Five
studies assessed exacerbations and one study did not address this
outcome at all (Hiremath 2006). None of the studies specifically
defined asthma exacerbations that conformed to our definition as
hospital admissions or visits to an emergency department or ad-
ditional course of corticosteroids and the description of exacerba-
tion varied between studies. Four studies defined asthma exacerba-
tions as increasing asthma symptoms requiring change or addition
of patient’s medication other than increasing rescue medication
(Pedersen 2006; Pedersen 2009; Vermeulen 2007; von Berg 2007)
and in one of these studies the patients with exacerbations were
withdrawn (Vermeulen 2007) and in two studies no definitions
of exacerbations were described. One study did not report adverse
events (Paunovic 2010). None of the studies reported on compli-
ance.
The four fully published studies were all supported or sponsored
by the manufacturer of ciclesonide. In all studies at least one of
the authors was an employee of the manufacturer that sponsored
the study.
Excluded studies
We excluded 21 records (see Characteristics of excluded studies).
Two studies were excluded because the intervention period in these
studies was two weeks (Agertoft 2010; Matsunaga 2009) and,
therefore, did not met our criteria of at least four weeks.
Risk of bias in included studies
The risk of bias of the included studies is summarised in Figure 2.
The risk of bias was unclear for the two studies that were published
as conference abstracts as no information was available to make
a definite judgement on the different items (Hiremath 2006;
Paunovic 2010). Our judgements for the remaining four studies
that were published in full text are discussed below per item.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The randomisation method was clearly described and adequate in
three studies (Pedersen 2006; Pedersen 2009; Vermeulen 2007).
One study did not provide sufficient information (von Berg 2007).
No study described allocation concealment and therefore the risk
of bias for this item was deemed unclear.
Blinding
The four fully published studies were described as double-blind
and double-dummy. Therefore, risk of bias was assessed as low
for both subjective outcomes and other outcomes (Pedersen 2006;
Pedersen 2009; Vermeulen 2007; von Berg 2007).
Incomplete outcome data
Loss to follow-up was reported in all four studies. In three stud-
ies, 4% of the randomised patients did not complete the study
(Pedersen 2009; Vermeulen 2007; von Berg 2007), only one study
gave a clear description of the number of patients per group and
the reasons for loss to follow-up (von Berg 2007). In one study, 8%
of the patients randomised terminated the study prematurely. The
number of patients per group was described; however, no reasons
for loss to follow-up were reported (Pedersen 2006). All studies
described that an intention-to-treat (ITT) analysis was performed
but no details of the analyses were provided and it was not specified
which values were imputed in the analyses. Therefore, risk of bias
for the items regarding incomplete outcome data were deemed un-
clear. Two of the four studies reported the number of patients that
violated the study protocol (Pedersen 2009; von Berg 2007). The
percentage of patients that violated the study protocol was similar
in the three different groups in the study of Pedersen 2009 (ci-
clesonide 80 µg = 6%; 160 µg = 7%; fluticasone 88 µg = 6%). In
the study of von Berg 2007 the percentage of patients that violated
the study protocol was also similar, 14% of the ITT population
in both groups. Two studies did not provide detailed information
on study protocol violations (Pedersen 2006; Vermeulen 2007).
Selective reporting
The four fully published studies all reported the outcomes that
were specified in their method section (Pedersen 2006; Pedersen
2009; Vermeulen 2007; von Berg 2007).
Other potential sources of bias
None of the four studies showed any obvious baseline differences,
therefore for all studies risk of other biases were rated low.
Effects of interventions
See: Summary of findings for the main comparisonCiclesonide
versus budesonide (dose ratio 1:2) for chronic asthma in children;
Summary of findings 2Ciclesonide versus fluticasone (dose ratio
1:1) for chronic asthma in children; Summary of findings 3
Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma
in children
Ciclesonide versus budesonide
Two studies assessed the effect of ciclesonide compared to budes-
onide both administered once daily at dose ratios of 1:2. The
dose of both ciclesonide and budesonide in one study (Vermeulen
2007) was twice the dose of the other study (von Berg 2007). Ci-
clesonide was delivered using a hydrofluoroalkane-propelled me-
tered dose inhaler (HFA-MDI) with the AeroChamber® spacer
in one study (von Berg 2007) and without a spacer in the other
study (Vermeulen 2007). In both studies, the comparator drug,
budesonide, was deliver using a Turbohaler®.
Both studies were designed to assess non-inferiority of ciclesonide
versus budesonide. One study used the per protocol (PP) popula-
tion to test for non-inferiority (Vermeulen 2007) and one study
based the primary analysis on the PP population and used the ITT
population to confirm the results (von Berg 2007). One study
set non-inferiority limits for lung function outcomes (FEV1: -
150 mL; forced vital capacity (FVC): -150 mL and PEF: -20 L/
minute), percentage of days without asthma symptoms and res-
cue medication (-8%) and quality of life measured with Standard-
ized Pediatric Asthma Quality of Life Questionnaire (PAQLQ(S))
scores (-0.5%) (Vermeulen 2007). One study set the non-infe-
riority acceptance limit for the outcome FEV1 at -100 mL, us-
ing the lower limit of 95% CI for differences between treatment
groups (von Berg 2007). The studies were considered to be clin-
ically similar and therefore data were pooled when possible. The
results are shown in Table 2 (see Summary of findings for themain
comparison).
Primary outcomes
Two studies on 1024 children found no significant differences be-
tween the groups regarding the outcome asthma symptoms (symp-
tom scores, asthma symptom and rescue medication-free days)
(see Table 2). Asthma symptom scores were assessed using 5-point
scales where a score of 0 represented no asthma symptoms and a
score of 4 very bad symptoms, unable to carry out daily activities.
One study reported asthma symptom scores as a median change
from baseline, which indicates skewed data and therefore we did
not perform a meta-analysis for this outcome.
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Pooled data for exacerbations (as defined in the original studies)
showed no significant difference between ciclesonide versus budes-
onide (RR 2.20, 95%CI 0.75 to 6.43; two studies; 1024 children)
(Analysis 1.1).
The occurrence of adverse effects was similar in both treatment
groups in one study on 621 children. Pharyngitis was one of
the most reported adverse effect (ciclesonide: 6.0%; budesonide:
6.8%) in this study (von Berg 2007). Adverse effects likely to be re-
lated to treatmentwere low in the study comparing ciclesonide 320
µg versus budesonide 800 µg; 0.7% and 0.8% for ciclesonide and
budesonide, respectively. This study also reported treatment emer-
gent adverse effects (including pharyngitis, asthma aggravated,
nasopharyngitis, upper respiratory tract infections) that were re-
ported inmore than 2% of the patients per group in a safety popu-
lation (N = 403) and found no difference between ciclesonide and
budesonide (RR 1.44, 95% CI 0.96 to 2.18) (Vermeulen 2007).
Pooling of data was not possible because definition of adverse ef-
fects were very different between the studies.
One study reported the outcome changes in body height after 12
weeks of intervention. Themeasurements were taken only in some
centres and selection criteria and procedures of the subgroup of
patients was not described. Height was measured by stadiometry
in 58 patients of the ciclesonide 160 µg group and 26 in the
budesonide 400 µg group. The study reported that the increase
in height was significantly bigger in the ciclesonide compared to
the budesonide group (1.18 cm versus 0.70 cm, respectively) (von
Berg 2007).
In the study that compared ciclesonide 160 µg once daily versus
budesonide 400µg once daily, one patient in each treatment group
terminated participation due to serious adverse effects, but the
author did not specify the nature of these effects (von Berg 2007).
Both studies (1024 children) reported that 24-hour urine cortisol
adjusted for creatinine levels showed a significant decrease in the
budesonide group compared to the ciclesonide group, but no nu-
merical data were reported.
Secondary outcomes
Both studies measured quality of life on the PAQLQ(S). One
study used the interview version (von Berg 2007) and in the other
study the PAQLQ(S) was self-administered (Vermeulen 2007).
Patients answered questions using a 7-point scale where a score
of 1 indicated maximum impairment and 7 indicated no impair-
ment. Pooled results showed no significant differences between
the groups (RR -0.00, 95% CI -0.09 to 0.09; two studies; 1010
children) (Analysis 1.2). One study on 621 children also assessed
quality of life using the self-administered Pediatric Asthma Care-
giver Quality of Life Questionnaire (PACQLQ). Carers answered
questions using a 7-point scale, where a score of 1 indicated max-
imum impairment and 7 indicated no impairment, and reported
one-sided superiority of ciclesonide but did not provide accep-
tance limits (von Berg 2007).
Pooled result of FEV1 (higher scores indicates better lung function)
showed no significant MD between groups (RR -0.02, 95% CI -
0.10 to 0.05; two studies; 1021 children) (Analysis 1.3).
Compliance and airway inflammation were not formally assessed
in either of the studies comparing ciclesonide versus budesonide.
Ciclesonide versus fluticasone propionate
Four studies assessed the effect of ciclesonide versus fluticasone
(Hiremath 2006; Paunovic 2010; Pedersen 2006; Pedersen 2009)
at a dose ratio of 1:1 and one study also assessed a dose ratio of 1:2
(ciclesonide 80 µg once daily compared to the fluticasone 88 µg
twice daily; Pedersen 2009). Ciclesonide was administered once
daily in all but one study that administered ciclesonide 80µg twice
a day (Pedersen 2006). One study did not report how either of the
study drugs were delivered (Paunovic 2010). In one study both
ciclesonide and fluticasone were delivered using an MDI with the
AeroChamber Plus® spacer (Hiremath 2006) and in the other two
studies both drugs were delivered using an HFA-MDI without a
spacer (Pedersen 2006; Pedersen 2009). Two studies were designed
to assess non-inferiority of ciclesonide. Both studies performed
a PP analysis and used an ITT analysis to test for robustness of
the results. In both studies, the non-inferiority limits were set for
the primary endpoint FEV1 at -0.100 L (Pedersen 2006; Pedersen
2009). In the study by Pedersen 2009, non-inferiority limits were
also set at 0.5 for PAQLQ(S) and PACQLQ scores; and +0.30
scores for asthma symptom score sum.
Of the four studies that assessed a dose ratio of 1:1, the study that
administered ciclesonide 80 µg twice daily (Pedersen 2006) was
considered to be clinically similar to the studies that administered
ciclesonide 160 µg once daily (Hiremath 2006; Paunovic 2010;
Pedersen 2009). Therefore, we pooled the data of these studies
where possible. The results are shown in Table 3.
Primary outcomes
Dose ratio 1:1
In two studies on 1048 children asthma symptom scores were
assessed using a 5-point scale where a score of 0 represented no
asthma symptoms and a score of 4 represented very bad symp-
toms, unable to carry out daily activities (Pedersen 2006; Pedersen
2009). The results could not be pooled since data were reported
as medians and this indicates skewed data. The other two stud-
ies on 932 children did not provide information on how asthma
symptoms were measured (Hiremath 2006; Paunovic 2010) (see:
Summary of findings 2).
No significant differenceswere found in asthma symptoms and res-
cue medication-free days (four studies; 1934 children) (Hiremath
2006; Paunovic 2010; Pedersen 2006; Pedersen 2009) and non-
inferiority of ciclesonide was confirmed (limit was set at 0.3) for
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asthma symptom scores in one study on 492 children (Pedersen
2009) (see Table 3).
Pooled data of two studies comparing ciclesonide 160 µg versus
fluticasone 88 µg twice daily showed no significant difference in
number of patients with exacerbations (RR 1.37, 95% CI 0.58 to
3.21; two studies; 1003 children) (Analysis 2.1) (Pedersen 2006;
Pedersen 2009). One study on 420 children reported that the
number of patients with exacerbations was similar in both the
ciclesonide and fluticasone groups (2.3% and 2.2%, respectively)
(Paunovic 2010).
One study on 492 children reported that five (2.1%) children
treated with ciclesonide 160 µg and two (0.8%) children treated
with fluticasone 88 µg twice daily discontinued the study prema-
turely due to asthma exacerbation (Pedersen 2009).
No significant difference in number of patients with adverse events
were found between ciclesonide 160 µg and fluticasone 88 µg
twice daily (RR 0.88, 95% CI 0.72 to 1.07; one study; 492 chil-
dren) (Analysis 2.2) (Pedersen 2009). The other two studies on
1023 children reported that adverse effects were similar in both
groups (Hiremath 2006; Pedersen 2006) and one study did not
assess adverse effects (Paunovic 2010).
The outcome 24-hour urine cortisol adjusted for creatinine levels
was reported in one study. No significant differences were found
for ciclesonide compared to fluticasone (MD 0.54 nmol/mmol,
95% CI -5.92 to 7.00; one study; 492 children) (Analysis 2.3).
Dose ratio 1:2
In one study on 502 children, no significant differences were found
in asthma symptoms and rescue medication-free days. For asthma
symptom sum scores non-inferiority (limit was set at 0.3) was
confirmed (Pedersen 2009)
The number of exacerbations was significantly higher in the ci-
clesonide 80 µg once-daily group compared to the fluticasone 88
µg twice-daily group (RR 3.57, 95% CI 1.35 to 9.47; one study;
502 children) (Analysis 2.1) (Pedersen 2009).
Thirteen (5.2%) participants treated with ciclesonide 80 µg and
two (0.8%) treated with fluticasone 88 µg discontinued the study
prematurely due to asthma exacerbation (Pedersen 2009).
No significant differences in number of patients with adverse ef-
fects were found between ciclesonide 80 µg once daily and flu-
ticasone 88 µg twice daily (RR 0.98, 95% CI 0.81 to 1.1; one
study; 502 children) (Analysis 2.2) (Pedersen 2009).
No significant difference was found for 24-hour urine cortisol
adjusted for creatinine levels in ciclesonide 80µg once daily versus
fluticasone 88 µg twice daily (MD 1.15 nmol/mmol, 95% CI
0.07 to 2.23; one study; 502 children) (Analysis 2.3).
Secondary outcomes
Dose ratio 1:1
Quality of life measured by the PAQLQ and the PACQLQ was
reported in one study on 492 children (Pedersen 2009). Patients
and carers answered questions using a 7-point scale where a score
of 1 indicated maximum impairment and 7 indicated no impair-
ment.
Non-inferiority was confirmed for both measurements for ci-
clesonide compared to fluticasone (P < 0.0001, one-sided) (
Pedersen 2009). Non-inferiority limits were set at -0.5 for the
PAQLQ scores and 15 for the PACQLQ scores. The other studies
did not formally assess quality of life.
Pooled data of two studies showed no significant difference in
FEV1 between ciclesonide 160 µg and fluticasone 88 µg (-0.01
L, 95% CI -0.04 to 0.02; two studies; 1000 children) (Analysis
2.4).
None of the studies formally assessed outcomes on compliance or
airway inflammation.
Dose ratio 1:2
Quality of life was measured by the PAQLQ(S) and the PAC-
QLQ. Patients and carers answered questions using a 7-point scale
where a score of 1 indicated maximum impairment and 7 indi-
cated no impairment. Non-inferiority of ciclesonide versus fluti-
casone was confirmed for both measurements (P < 0.0001, one-
sided) (Pedersen 2009).
Results were similar in both groups and non-significant for FEV1
(higher FEV1 indicates better lung function) and non-inferiority
was confirmed (MD -0.05 L, 95% CI -0.11 to 0.01; one study;
499 children) (Analysis 2.4) (limits set at -100 L) (Pedersen 2009).
The outcomes compliance or airway inflammation were not for-
mally assessed.
It was not possible to conduct subgroup or sensitivity analyses due
to lack of sufficient data.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children
Patient or population: pat ients with chronic asthma in children
Settings: all sett ings
Intervention: ciclesonide
Comparison: f lut icasone (dose rat io 1:1)




Quality of the evidence
(GRADE)
Comments






score (scale 0 to 4)
Follow-up: 12 weeks




2 studies used a 5-
point scale and 1 study
did not provide details
how asthma symptoms
were measured. Data
could not be pooled due
to diversity in scales
Patients with exacer-
bations
Number of pat ients
with exacerbat ions
Follow-up: 12 weeks









Number of pat ients
with adverse events
Follow-up: 12 weeks
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Two fully published studies were sponsored by the manufacturer and at least one of the authors of each study was an
employee of the manufacturer that sponsored the study.
2 The intervent ion period of 12 weeks is too short to expect any major changes in this outcome.











































































































Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children
Patient or population: pat ients with chronic asthma in children
Settings: all sett ings
Intervention: ciclesonide
Comparison: f lut icasone (dose rat io 1:2)




Quality of the evidence
(GRADE)
Comments






score (scale 0 to 4)
Follow-up: 12 weeks
The mean asthma




symptom in the inter-
vent ion groups was
0.07 higher










Number of pat ients
with exacerbat ions
Follow-up: 12 weeks









Number of pat ients
with adverse events
Follow-up: 12 weeks
476 per 1000 471 per 1000
(424 to 514)




* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).











































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Based on one study that was underpowered for a non-inferiority trial.
2 The study was sponsored by the manufacturer and at least one author was an employee of the manufacturer that sponsored
the study.












































































































D I S C U S S I O N
Summary of main results
In this review we assessed the efficacy and safety of ciclesonide
compared to other ICS (budesonide and fluticasone) at a dose
ratio 1:1 and 1:2 in the treatment of children younger than 18
years of age with chronic asthma. We found six studies including
3256 children that met our inclusion criteria.
We found no significant differences in efficacy between ciclesonide
and fluticasone or budesonide for asthma symptoms and exacer-
bations after 12 weeks of treatment, except for one study com-
paring ciclesonide versus fluticasone (1:2) that found significantly
more exacerbations in the ciclesonide group. Adherence was not
assessed in the studies.
With regards to safety, local side effects such as pharyngitis were
seen in both treatment groups with no significant differences, even
in the study using a very high dose of budesonide (800 µg) ad-
ministered once daily. Looking at systemic side effects, one study
showed a significant improvement in height in the ciclesonide
group compared to the budesonide group after 12 weeks of in-
tervention, but measurements were only performed in a subset of
patients. Studies assessing 24-hour urinary cortisol levels showed
either less suppression (ciclesonide versus budesonide) or no sig-
nificant difference (ciclesonide versus fluticasone).
Overall completeness and applicability of
evidence
Only six studies fulfilled our inclusion criteria, of which two stud-
ies were only published in abstract form, with limited details avail-
able concerning the participants enrolled, definition of outcome
measures and trial methodology. The studies were mainly per-
formed in Eastern European countries and South-Africa, where
fewer children might have received ICS treatment before enrol-
ment in the studies than in western European countries. Patients
included in the published studies were aged four to 15 years and
diagnosed with chronic moderate-to-severe asthma according to
ATS/GINA criteria, with a relatively poor FEV1 as a requirement
at study entry in most of the included studies. No studies com-
paring ciclesonide versus HFA-BDP were found. Different doses
of both ciclesonide and comparator ICS were used; ciclesonide
80 to 320 µg, budesonide 400 to 800 µg, and fluticasone 88 to
176 µg in a pMDI-AeroChamber Plus® combination (flutica-
sone, ciclesonide), as a pMDI without a spacer (fluticasone, ci-
clesonide) or DPI (budesonide). Current evidence is insufficient
to recommend the optimal doses of ICS. Studies comparing dif-
ferent ICS doses could not reveal a clear dose-response relationship
in terms of efficacy and safety in children with mild-to-moderate
asthma (Zhang 2011). However, all ICS doses in the studies were
within accepted ranges for children. Fluticasone and ciclesonide
are not registered with the AeroChamber Plus®; further, the use
of a pMDI without a spacer is discouraged with children. Because
all these different combinations were used, it is not known which
part of the effect can be attributed to the ICS used and which
part to the inhaler used and the conclusions are only valid for the
chosen comparisons.
In all studies for the outcome adverse effects, 24-hour urinary cor-
tisol levels was measured. The clinical relevance of lower 24-hour
urinary cortisol levels for patients and practitioners is unclear and
more important is the ability of the adrenal cortex to be able to
respond to stressful circumstances, such as an infection, fever, etc.
The most appropriate test would then be the more invasive low-
dose adrenocorticotropic hormone (ACTH) (Synacthen) stimula-
tion test, which is more sensitive in detecting adrenal impairment
(Crowley 1991; Lipworth 1999). However, for relevant systemic
adverse effects, such as growth and adrenal insufficiency, a follow-
up period of 12 weeks is too short.
One study was published assessing the long-term safety of ci-
clesonide (Skoner 2008). This RCT was not included in this re-
view, because it compared ciclesonide to placebo. Mean linear
growth velocity and 24-hour urinary cortisol levels were similar in
the three groups after one year. However, this study could not pro-
vide enough reassurance about safety, as considerable concern was
expressed about compliance of the children as their asthma was
very mild and the study failed to show any benefit of ciclesonide
in terms of lung function or asthma control (Chapman 2008;
Malozowski 2008).
All studies included in this review were designed as non-inferi-
ority trials. The allowance of setting pre-defined non-inferiority
acceptance limits the concern is that drugs that are less effective
will be classified as non-inferior or as effective as the control drug.
A trial showing non-inferiority of the experimental drug suggests
that the experimental drug is as good as the standard treatment.
However, the width of the pre-defined margins of inferiority has
to be taken into account when interpreting the results of these
trials individually. Wide margins can result in concluding that the
experimental treatment is equally beneficial when it is really less
beneficial. Additionally, non-inferiority should be assessed for rel-
evant outcomes, with a sufficiently long treatment and follow-up
period.
Not all of the included studies in our review provided non-infe-
riority acceptance limits for our primary outcomes. Additionally
most of the non-inferiority limits were hard to interpret for rea-
sons such as unclear description of the outcome measure (asthma
symptom scores) and no information available on clinical impor-
tant difference of the questionnaire (PACQLQ). To help readers
of this review interpret data of individual studies we provided pre-
defined non-inferiority limits where possible.
The results of the primary studies are focused on non-inferiority
of ciclesonide versus another ICS. However, when data could be
pooled non-inferiority was not a concern anymore since the point
estimate and CI are not influenced by the acceptance limits set in
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the individual studies. In addition, a meta-analysis of non-inferi-
ority studies showed that drugs that were found non-inferior in
published RCTs were not shown to be systematically less effective
than standard treatments (Soonawala 2010).
Quality of the evidence
Using recommendations in the Cochrane Handbook and from
the GRADE working group, we judged that the quality of the ev-
idence was ’low’ for the outcomes asthma symptoms and adverse
events and ’very low’ for the outcome exacerbations for ciclesonide
versus budesonide (dose ratio 1:1; Summary of findings table 1).
The quality of evidence was graded ’moderate for the outcome
asthma symptoms, ’very low’ for the outcome exacerbations and
’low’ for the outcome adverse events for ciclesonide versus flutica-
sone (dose ratio 1:1; Summary of findings table 2). For ciclesonide
versus fluticasone (dose ratio 1:2) the quality was rated ’low’ for
the outcome asthma symptoms and ’very low’ for exacerbations
and adverse events (dose ratio 1:2; Summary of findings table 3).
The evidence was regarded TO BE indirect due to the fact that in
all studies the outcomes were measured after a 12-week interven-
tion period, which was regarded as an insufficient period to expect
an effect on the outcomes adverse events and exacerbations.
Potential biases in the review process
We used the methods described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b) to prevent or
restrict the risk of bias in our review process. A comprehensive
search of the literature searching several databases was conducted.
We are confident that all relevant published studies for this review
were found. We did attempt to find study protocols by searching
www.clinicalstudyresults.org. We included six studies and there-
forewe couldnot generate funnel plots to identify publication bias.
We contacted study authors in an attempt to find additional data,
but did not receive any. Two review authors independently per-
formed study selection, data collection, risk of bias and GRADE
assessment to minimise bias. We did not write a protocol for this
review but used the protocol of the review of Manning 2009. Any
changes to this protocol are listed in the following section of this
review (Differences between protocol and review).
Agreements and disagreements with other
studies or reviews
Our findings are largely in keeping with other reviews on small
particle size and reviews in adult patients. The systematic review
by Manning 2009 comparing ciclesonide to other ICS in adults
reached the same conclusions on efficacy outcomes; ciclesonide
is equal to budesonide/fluticasone in terms of lung function end
points, but for our primary outcomes this could not be established
due towideCIs (Manning 2009). The results of this review are also
similar to the reported results on the outcomes FEV1 andquality of
life in a narrative review that discusses ciclesonide as a treatment for
asthma in adults and children (Dahl 2006). In this narrative review,
the authors reported that in children the efficacy of ciclesonide
was equivalent to fluticasone for the outcomes FEV1 and quality
of life (Dahl 2006). A contrast with Manning 2009 and Dahl
2006 was the lower oral candidiasis with ciclesonide compared to
fluticasone in adults, which we did not find in children. Other
reviews comparing small-particle-size ICS with normal-particle-
size ICS so far could not identify improved efficacy or safety on
relevant end points compared to normal-particle-size ICS (Adams
2007).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A beneficial effect on asthma symptoms, exacerbations and side
effects of ciclesonide versus budesonide or fluticasone could be
neither demonstrated nor refuted. Ciclesonide was non-inferior
compared to budesonide or fluticasone in terms of lung function
end points and in some studies less suppression on cortisol out-
comes was demonstrated.
New medications should either be more effective, safer or cheaper
before they can be recommended for clinical practice. Because
older medications have been used for longer periods of time,
more knowledge is available on their long-term safety and they
are usually cheaper than new drugs (resource use). As far as we
are aware there were few data available for the cost-effectiveness of
ciclesonide compared to other ICS.
Several other considerations must be taken into account before
making clinical decisions, such as the trade-off between bene-
fits and harms, patient preferences and values, and resource use.
The importance of these considerations can differ among differ-
ent countries and cultures, leading to different recommendations
for practice. For patient and parents, long-term safety of ICS is
an important issue. Well-designed long-term safety studies for ci-
clesonide are lacking. We cannot exclude that children receiving
ciclesonide experiencemore exacerbations, as the CIs included po-
tential harm as well as benefit. Therefore, the trade-off between
benefits and harms of using ciclesonide instead of budesonide or
fluticasone is unclear.
An advantage of ciclesonide over other ICS is that it is licensed
for once-daily use, which could enhance compliance (Osterberg
2005), particularly in patients where compliance is a problem. Al-
though ciclesonide is not registered for use with an AeroCham-
ber® in paediatric practice, it is common to use a spacer de-
vice and AeroChamber Plus® is an adequate choice based on the
21Ciclesonide versus other inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
low plume velocity of the ciclesonide-pMDI. In addition, several
studies have also used an AeroChamber® to deliver ciclesonide
(Hiremath 2006; Pedersen 2010; von Berg 2007). In the end, re-
source use or costs of different ICS should be considered in final
decision making.
Implications for research
Based on this review a number of recommendations can be made
for future trials. First, instead of non-inferiority studies, superior-
ity trials are needed to identify the efficacy and safety of ciclesonide
compared to other ICS. In addition, these studies should be pow-
ered for patient-relevant outcomes (exacerbations, asthma symp-
toms, quality of life and side effects) and not only on surrogate
endpoints such as lung function and cortisol.
Studies comparing ciclesonide once daily with other ICS twice
daily should be conducted, to test the advantages of ciclesonide
being a pro-drug that can be administered once daily. Once daily
administration versus twice daily may result in increased adher-
ence and to increased control of asthma and fewer side effects. In
general, studies of at least six to 12 months’ duration are needed
to compare the relative benefits and side effects of the various ICS
and their ways of administration on the longer term. Finally, in-
haler devices and inhaler techniques needs to be taken into con-
sideration in designing future trials and ideally, two doses of each
drug-device combination should be compared to two doses of the
comparator drug-device combination.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hiremath 2006
Methods Design: randomised controlled trial following a baseline period of 2 to 4 weeks (rescue
medication only) and an intervention period of 12 weeks
Location and number of centres: not reported
Participants Number screened: not reported
Number randomised: 512
Number completed: not reported
Age: children and adolescents (4 to 15 years) with predominantly moderate-to-severe
asthma
Gender: not reported
Asthma severity: forced expiratory volume in 1 second (FEV1) 50-90% of predicted
Inclusion/exclusion criteria: not reported
Interventions Ciclesonide 160 µg (ex-actuator; N = 254) once daily in the evening
Fluticasone 88 µg twice daily (176 µg/day, ex-actuator; N = 258)
Delivery: both medications were administered via a metered-dose inhaler with spacer
(AeroChamber Plus®)
Inhalation technique: not reported
Treatment period: 12 weeks (following 2 to 4 weeks’ baseline period rescue medication
only)
Allowed asthma medication: not reported
Outcomes FEV1 from baseline to the end of the treatment period, morning peak expiratory flow,
median percentage of asthma symptom- and rescue medication-free days and incidence
of adverse events
Notes Incomplete data since this study was only published as an abstract
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not described
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Hiremath 2006 (Continued)
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not enough information
Other bias Unclear risk Not enough information
Paunovic 2010
Methods Design: randomised, double-blind, 2 parallel-group study
Location and number of centres: not reported
Participants Number screened: not reported
Number randomised: 420
Number completed: not reported
Age: 7 to 12 years
Gender: not reported
Asthma severity: FEV1 50-90% of predicted
Inclusion/exclusion criteria: not described
Interventions 1. Ciclesonide once daily (160 µg/day)
2. Fluticasone twice daily (176 µg/day)
Delivery: not reported
Inhalation technique: not reported
Treatment period: 12 weeks (following 2 to 4 weeks baseline period rescue medication
only)
Allowed asthma medication: not reported
Outcomes Forced expiratory volume in 1 second (FEV1) (mL), peak expiratory flow (PEF) (L/
minute), asthma symptom scores, rescue medication use, asthma exacerbation
Notes Incomplete data since this study was only published as an abstract
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described
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Paunovic 2010 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not enough information
Other bias Unclear risk Not enough information
Pedersen 2006
Methods Design: 12-week, randomised, multicentre, double-blind, double-dummy, 2-arm, par-
allel group study, with a 2- to 4-week baseline period
Location and number of centres: 51 centres in Europe, South Africa and Canada
Participants Number screened: 728 enrolled
Number randomised: 556 (baseline details given for per-protocol set. Ciclesonide: N =
277; fluticasone: N = 279)
Number completed: not reported.
Age: median 10 years
Gender: 331 boys; 180 girls
Baseline details: add-on therapy prior to baseline: ciclesonide N = 80, 64%; fluticasone
N = 170, 66%; inhaled corticosteroid (ICS) therapy prior to baseline: ciclesonide N =
162, 31%; fluticasone N = 67, 27%; mean ICS dose: 390 µg/day overall; mean forced
expiratory volume in 1 second (FEV1): 1.7 L overall; mean FEV1 % predicted: 80%
overall; mean reversibility change in FEV1: 20%
Inclusion criteria: aged 6 to 15 years; persistent asthma for at least 6 months (Ameri-
can Thoracic Society criteria); clinically stable for 4 weeks prior to study entry; FEV1
predicted: 50-90% rescue medication only, 80-100% in patients treated with ICS only;
symptom score > 1 on 6 of last 10 days of run-in; adequate metered dose inhaler (MDI)
device technique without spacer
Exclusion criteria: history of life-threatening asthma; 2 ormore inpatient hospitalisations
in previous year; > 60 days of systemic corticosteroids in past year; > 400 budesonide or
equivalent/day in 30 days prior to baseline; > 8 puffs short-acting beta2-agonist/day for
3 consecutive days during run-in
Interventions 1. Ciclesonide 100 µg twice daily
2. Fluticasone 100 µg twice daily
Delivery: hydro-fluoroalkane metered dose inhaler
Inhalation technique: adequate inhalation technique no details described
Treatment period: 12 weeks (following 2- to 4-week baseline period with rescue medi-
cation (beta2 agonist only)
Allowed asthma medication: not reported
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Pedersen 2006 (Continued)
Outcomes FEV1, clinic peak expiratory flow (PEF), a.m. PEF, p.m. PEF, symptoms, rescue medi-
cation usage, adverse events
Notes Analysis of co-variance included age and randomisation values as co-variates and sex,
treatment, and region/country as fixed factors
Funding: Grant sponsor: ALTANA Pharma AG, Konstanz, Germany. This study was
supported by ALTANA Pharma, Konstanz, Germany. The authors would like to thank
Pro Ed Communications, Inc., Beachwood, also all Medicus International, London, UK
for their editorial assistance. Editorial support was funded by ALTANA Pharma. Dr.
Søren Pedersen has received remuneration for lectures from AstraZeneca and Glaxo-
SmithKline and served as a paid consultant for ALTANA Pharma and AstraZeneca. Ilse
Theron is an employee of ALTANA Madaus Ltd, Woodmead, South Africa. Dr. Renate
Engelstatter is an employee of ALTANA Pharma AG, Konstanz, Germany
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was based on a
computer-generated list (Program RAN-
DOM) provided to the study centres by
ALTANA Pharma AG (Konstanz, Ger-
many)”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Low risk Quote: “Neither the investigator nor any-
one at the study centre knew whether ci-
clesonide or fluticasone was administered”
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Quote: “Neither the investigator nor any-
one at the study centre knew whether ci-
clesonide or fluticasone was administered”
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described which values used in inten-
tion-to-treat (ITT) analysis
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described which values used in ITT
analysis
Selective reporting (reporting bias) Low risk The results of all outcomes described in
methods were reported
Other bias Low risk Small differences in baseline characteristics
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Pedersen 2009
Methods Design: 12-week, randomised, double-blind, double-dummy, 3-arm, parallel-group
study, following a 2- to 4-week run-in period
Location and number of centres: 50 centres in Brazil, Germany, Hungary, Poland, Por-
tugal and South Africa
Participants Number screened: 904 enrolled
Number randomised: 744 randomised and entered treatment period
Number completed: 33patients terminated study, 711 completed (of the 744, 50 violated
protocol leaving 694 in per protocol population)
Age: 6 to 11 years; median age in each group 9 years (range: 6 to 11)
Gender: 170 boys; 161 girls
Inclusion criteria: outpatients aged 6 to 11 years with a history of persistent bronchial
asthma, for ≥ 6 months were eligible for participation. To be entered into the treatment
period, patients were required to have a forced expiratory volume in 1 second (FEV1)
50-90% of predicted and a FEV1 reversibility of ≥ 12% after inhalation of salbutamol
200 to 400 mg at the end of the run-in period. In addition, patients had to present
asthma symptoms on at least 6 of the last 10 consecutive days of the baseline period, or
to use at least 8 puffs of rescue medication within the last 10 consecutive days of the
baseline period. Furthermore, patients had to demonstrate a good inhalation technique
when using a metered dose inhaler (MDI) without a spacer
Exclusion criteria: a history of near-fatal asthma that required intubation; a respiratory
tract infection or asthma exacerbation within the last 30 days prior to study entry;
more than 2 inpatient hospitalisations for asthma in the previous year; use of systemic
corticosteroids during the study, within the last 30 days prior to study entry or for more
than 60 days in the previous 2 years
Interventions 1. Ciclesonide MDI (80 µg once daily) (N = 252)
2. Ciclesonide 160 MDI (160 µg once daily) (N = 242)
Both: in the evening (ex-actuator; equivalent to 100 and 200 µg ex-valve)
3. Fluticasone MDI (88 µg twice daily) (N = 250) - fluticasone 176 (ex-actuator; equiv-
alent to 100 µg twice daily ex-valve) in the morning and evening without a spacer
Delivery: administered via HFA134-a MDIs
Inhalation technique: good inhalation technique, no details described
Treatment period: a run-in period (of at least 2 weeks and up to 4 weeks), in which
eligible patients discontinued previous inhaled corticosteroids (ICS) and other controller
medications followed by a 12-week treatment period
Allowed asthma medication: rescue medication salbutamol, patients were allowed to
continue regular nasal corticosteroids at a constant dose
Outcomes Change in FEV1 (L), peak expiratory flow (PEF) (L/minute), PD20FEV1 to metha-
choline (bronchial provocation test with methacholine to assess the provocative dose
producing a 20% fall of FEV1) was performed at a subgroup of sites, Pediatric Asthma
Quality of Life Questionnaire (PAQLQ) and Pediatric Asthma Caregiver’s Quality of
Life Questionnaire (PACQLQ), asthma symptom scores and use of rescue medication
(salbutamol), safety was assessed by adverse effect reporting, physical examination, vital
signs and laboratory investigations, including haematology, urinalysis and biochemistry
Notes Analysis of co-variance included treatment, gender and centre pool as fixed factors and
baseline value and age as co-variates
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Pedersen 2009 (Continued)
Funding: Professor S. Pedersen has received consultancy fees and lecture honoraria from
Nycomed and GlaxoSmithKline, and has worked on research projects supported by
Nycomed, GlaxoSmithKline and AstraZeneca. Dr R. Engelstatter and Dr S. Hirsch
are employees of Nycomed. Dr H.-J. Weber was an employee of Nycomed at the time
of writing of the manuscript. Professor A. Emeryk has received consultancy fees from
Nycomed and lecture honoraria from Nycomed, GlaxoSmithKline and AstraZeneca,
and has
worked on research projects supported by Nycomed, Thorax-Chisei and Pierre Fabre
Medicament. Dr J. Vermeulen has worked on research projects supported by Nycomed.
Professor L. Barkai and Dr H. Weber have nothing to disclose
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “…a 1:1:1 randomisation scheme
by means of a computer generated ran-
domisation list.….”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Low risk Double-blind and double-dummy design
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Ciclesonide provided in the evening 1 or 2
puffs and fluticasone was administered in
the morning and evening
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described which values used in inten-
tion-to-treat (ITT) analysis
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described which values used in ITT
analysis
Selective reporting (reporting bias) Low risk The results of all outcomes described in
methods were reported
Other bias Low risk No obvious baseline differences
Vermeulen 2007
Methods Design: 12-week, randomised, double-blind, double-dummy, parallel-group study, fol-
lowing
a 2-week run-in period
Location and number of centres: 31 centres in Europe and South Africa
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Vermeulen 2007 (Continued)
Participants Number screened: 431
Number randomised: 403 (ciclesonide: 272; budesonide: 131)
Number completed: 384
Age: median 14 years
Gender: 272 boys; 131 girls
Astma severity: forced expiratory volume in 1 second (FEV1) 73% predicted
Inclusion criteria: 12 to 17 years old; FEV1 50-80% predicted; severe asthma (GINA
2003 definition); not well controlled after constant treatment with fixed-dose budes-
onide 400 mg/day (or equivalent) 4 weeks prior to study entry with FEV1 45-80%
predicted; Alternatively constant treatment with fixed-dose budesonide 400 to 800 mg/
day (or equivalent) 4 weeks prior to study entry, with FEV1 46-85% predicted; entry
into treatment period at randomisation (baseline), FEV1 50-80% predicted, FEV1 re-
versibility > 15%
salbutamol.
Exclusion criteria: oral corticosteroids within 4 weeks of study entry; concomitant severe
diseases; relevant lung diseases or clinically relevant abnormal laboratory values; > 10
cigarette pack-year smoking history; females of child-bearing potential without contra-
ception
Interventions 1. Ciclesonide 400 µg once daily
2. Budesonide 800 µg once daily
Delivery:HFA-MDI (ciclesonide); Turbohaler® dry powder inhaler (DPI) (budesonide)
Inhalation technique: not described
Treatment period: 12 weeks
Allowed asthma medication: not reported
% on inhaled corticosteroids (ICS): 100
Outcomes FEV1; peak expiratory flow (PEF); 24-hour urinary free cortisol concentrations
Notes Analysis of co-variance included baseline value, treatment, age, sex and country pool as
co-variates or factors (not specified)
Funding: this study (EudraCT No: 2004- 001233-41) was sponsored by ALTANA
Pharma. ALTANA Pharma had a role in the study design, the collection, analysis and
interpretation of the data and was involved in the writing of the report and the decision
to submit the manuscript. The co-authors H. Rauerc and R. Engelstatter were both
employees of ALTANA Pharma
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the randomisation list was gener-
ated by the sponsor using a multiplicative
congruential pseudo-random number gen-
erator withmodulus 231-1 (ProgramRAN-
DOM based on Fishman and Moore”
Allocation concealment (selection bias) Unclear risk No information provided
33Ciclesonide versus other inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vermeulen 2007 (Continued)
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Low risk Double-blind and double-dummy design
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Double-dummy but ciclesonide was ad-
ministered in 2 puffs with metered dose in-
haler (MDI) and budesonide with Turbo-
haler® device 4 inhalations
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described which values used in inten-
tion-to-treat (ITT) analysis
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described which values used in ITT
analysis
Selective reporting (reporting bias) Low risk The results of all outcomes described in
methods were reported
Other bias Low risk No obvious baseline differences
von Berg 2007
Methods Design: 12-week, randomised, double-blind, double-dummy, 2-arm, parallel-group
study, following
a 2- to 4-week run-in period
Location and number of centres: 59 centres in Europe and South Africa
Participants Number screened: 774
Number randomised: 621 (ciclesonide: 416; budesonide: 205)
Number completed: 594
Age: mean 9 years
Gender: 395 boys; 226 girls
Astma severity: forced expiratory volume in 1 second (FEV1) 78% predicted; inhaled
corticosteroid (ICS) treatment: 51%
Inclusion criteria: aged 6 to 11 years; diagnosis of persistent asthma for 6 months; FEV1
> 50-90% predicted if rescue medication only, > 50-100% predicted if using constant
dose of controller medication other than corticosteroids for 1 month; FEV1 80%-105%
predicted if using ≤ 400 µg/day beclomethasone dipropionate equivalent for 1 month
before inclusion. Post-run-in: FEV1 50-90% predicted after withholding short-acting
beta2-agonist (SABA) for at least 4 hours; reversibility of FEV1 > 12% of initial post-
SABA; asthma symptom scores > 1 on at least 6 of previous 10 days or use of > 8 puffs
of rescue medication during the previous 10 days
Exclusion criteria: history of life-threatening asthma, concomitant severe diseases; 2 or
more hospitalisations for asthmawithin previous 12months; asthma exacerbation during
4 weeks before baseline; systemic corticosteroids during 30 days before baseline; use of
systemic corticosteroids for more than 60 days within the previous 2 years; participation
in another study within 30 days before baseline. No other asthma medication permitted
during study
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von Berg 2007 (Continued)
Interventions 1. Ciclesonide 200 µg once daily
2. Budesonide 400 µg once daily
Delivery: ciclesonide: hydro-fluoroalkane metered dose inhaler (HFA-MDI) (+ Ae-
roChamber®); budesonide: Pulmicort Turbohaler®
Inhalation technique: not described
Treatment period: 12 weeks
Allowed co-medication: none
% on ICS: not reported
Outcomes FEV1, peak expiratory flow, asthma symptoms, rescue medication, bone growth, 24-
hour urinary cortisol, adverse events
Notes Analysis of co-variance included baseline value at randomisations visit and age as co-
variates
Funding: this study was funded and sponsored by ALTANA Pharma. The authors would
like to thank ProEd Communications, Inc., Beachwood Ohio and Medicus Interna-
tional, London, UK, for their editorial assistance. Editorial support was funded by AL-
TANA Pharma. The co-authors Renate Engelstatter Stefan Leichtl, StefanHellbardt and
Thomas D. Bethke were employees of ALTANA Pharma
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were randomised
at a ratio of 2:1…”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Outcomes 1, 3, 4, 5
Low risk Double-blind and double-dummy design
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Double-blind, double-dummy, not speci-
fied who was blinded
Ciclesonide and budesonide were adminis-
tered in the evening via an HFA-MDI with
an AeroChamber Plus® spacer and Pulmi-
cort Turbohaler®, respectively
Incomplete outcome data (attrition bias)
Outcomes 1, 3, 4, 5
Unclear risk Not described which values used in inten-
tion-to-treat (ITT) analysis
Incomplete outcome data (attrition bias)
Other outcomes
Unclear risk Not described which values used in ITT
analysis
Selective reporting (reporting bias) Low risk The results of all outcomes described in
methods were reported
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von Berg 2007 (Continued)
Other bias Low risk No obvious baseline differences
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adachi 2006 Children not analysed separately
Agertoft 2010 Treatment < 4 weeks
Bateman 2008 Children not analysed separately
Berger 2009 Placebo controlled
BY9010/M1-207 Children not analysed separately
Cohen 2011 Placebo controlled
Dahl 2010 Children not analysed separately
Derom 2009 Included patients > 18 years of age
Dusser 2007 Included patients > 18 years of age
Erin 2008 Included patients > 18 years of age
Gelfand 2006 Placebo controlled
Hoshino 2010 Included patients > 18 years of age
Knox 2007 Children not analysed separately
Kosztyla-Hojna 2007 Included patients > 18 years of age
Malozowski 2008 Not a randomised controlled trial
Matsunaga 2009 Treatment < 4 weeks
Meltzer 2009 Placebo controlled
Molen 2010 Children not analysed separately
Pedersen 2010 Placebo controlled
Postma 2011 Children not analysed separately
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(Continued)
Skoner 2006 Placebo controlled
Stoica 2010 Children not analysed separately
van den Berge 2009 Included patients > 18 years of age
Characteristics of studies awaiting assessment [author-defined order]
BY9010/M1-205
Methods Randomised controlled trial, double-blind, study duration consists of a baseline period (2 to 4 weeks) and a treatment
period (12 weeks)
Participants Children aged 4 to 15 years
Main inclusion criteria: history of persistent bronchial asthma for at least 6 months, forced expiratory volume in one
second (FEV1) 50-90% of predicted
Main exclusion criteria: concomitant severe diseases or diseases which are contraindications for the use of inhaled
corticosteroids; chronic obstructive pulmonary disease (chronic bronchitis or emphysema), other relevant lungdiseases
causing alternating impairment in lung function, or a combination; respiratory tract infection or asthma exacerbation
within the last 30 days prior to entry into the study; history of life-threatening asthma; premature birth; current
smoking; smoking history with either ≥ 10 pack-years; pregnancy; intention to become pregnant during the course
of the study; breast feeding; lack of safe contraception
Interventions Ciclesonide 200 µg/day
Fluticasone propionate 200 µg/day
Outcomes Primary outcome measures: FEV1 absolute values
Secondary outcome measures: FEV1 as % of predicted, peak expiratory flow (PEF) from spirometry, diary-based
morning and evening PEF, diary-based symptom score, diary-based salbutamol metered dose inhaler (MDI) use,
diurnal PEF fluctuation, drop-out rate due to asthma exacerbations, time until asthma exacerbation, number of
symptom-free and rescue medication-free days, number of days with asthma control, physical examination, vital
signs, laboratory work-up, adverse events
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Ciclesonide versus budesonide (dose ratio 1:2)




participants Statistical method Effect size
1 Patients with exacerbations 2 1024 Risk Ratio (M-H, Fixed, 95% CI) 2.20 [0.75, 6.43]
2 Quality of life PAQLQ (S) 2 1010 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.09, 0.09]
3 FEV1 least square means (L) 2 1021 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.10, 0.05]
Comparison 2. Ciclesonide versus fluticasone




participants Statistical method Effect size
1 Patients with exacerbations 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Dose ratio 1:1 2 1003 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.58, 3.21]
1.2 Dose ratio 1:2 1 502 Risk Ratio (M-H, Fixed, 95% CI) 3.57 [1.35, 9.47]
2 Adverse events: number of
patients with adverse events
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Dose ratio 1:1 1 492 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.72, 1.07]
2.2 Dose ratio 1:2 1 502 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.81, 1.17]
3 Adverse events: 24-hour urine
free cortisol adjusted for
creatinine (nmol/mmol)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Dose ratio 1:1 1 492 Mean Difference (IV, Fixed, 95% CI) 0.54 [-5.92, 7.00]
3.2 Dose ratio 1:2 1 502 Mean Difference (IV, Fixed, 95% CI) 1.15 [0.07, 2.23]
4 Generic FEV1 least square mean
(L)
2 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 Dose ratio 1:1 2 1000 Mean Difference (Fixed, 95% CI) -0.01 [-0.04, 0.02]
4.2 Dose ratio 1:2 1 499 Mean Difference (Fixed, 95% CI) -0.05 [-0.11, 0.01]
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Analysis 1.1. Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 1 Patients with
exacerbations.
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 1 Ciclesonide versus budesonide (dose ratio 1:2)
Outcome: 1 Patients with exacerbations
Study or subgroup Ciclesonide Budesonide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vermeulen 2007 7/272 2/131 50.2 % 1.69 [ 0.36, 8.00 ]
von Berg 2007 11/416 2/205 49.8 % 2.71 [ 0.61, 12.11 ]
Total (95% CI) 688 336 100.0 % 2.20 [ 0.75, 6.43 ]
Total events: 18 (Ciclesonide), 4 (Budesonide)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours ciclesonide Favours budesonide
Analysis 1.2. Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 2 Quality of life
PAQLQ (S).
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 1 Ciclesonide versus budesonide (dose ratio 1:2)
Outcome: 2 Quality of life PAQLQ (S)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vermeulen 2007 262 0.19 (0.8093) 127 0.18 (0.6762) 34.1 % 0.01 [ -0.14, 0.16 ]
von Berg 2007 416 0.69 (0.6577) 205 0.7 (0.6577) 65.9 % -0.01 [ -0.12, 0.10 ]
Total (95% CI) 678 332 100.0 % 0.00 [ -0.09, 0.09 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours budesonide Favours ciclesonid
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Analysis 1.3. Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 3 FEV1 least square
means (L).
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 1 Ciclesonide versus budesonide (dose ratio 1:2)
Outcome: 3 FEV1 least square means (L)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vermeulen 2007 270 0.505 (0.5587) 130 0.54 (0.5131) 46.2 % -0.03 [ -0.14, 0.08 ]
von Berg 2007 416 0.232 (0.4692) 205 0.25 (0.6727) 53.8 % -0.02 [ -0.12, 0.08 ]
Total (95% CI) 686 335 100.0 % -0.02 [ -0.10, 0.05 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours budesonide Favours ciclesonide
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Analysis 2.1. Comparison 2 Ciclesonide versus fluticasone, Outcome 1 Patients with exacerbations.
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 2 Ciclesonide versus fluticasone
Outcome: 1 Patients with exacerbations
Study or subgroup Ciclesonide Fluticasonel Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dose ratio 1:1
Pedersen 2006 5/254 4/257 44.7 % 1.26 [ 0.34, 4.66 ]
Pedersen 2009 7/242 5/250 55.3 % 1.45 [ 0.47, 4.49 ]
Subtotal (95% CI) 496 507 100.0 % 1.37 [ 0.58, 3.21 ]
Total events: 12 (Ciclesonide), 9 (Fluticasonel)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Dose ratio 1:2
Pedersen 2009 18/252 5/250 100.0 % 3.57 [ 1.35, 9.47 ]
Subtotal (95% CI) 252 250 100.0 % 3.57 [ 1.35, 9.47 ]
Total events: 18 (Ciclesonide), 5 (Fluticasonel)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
0.01 0.1 1 10 100
Favours ciclesonide Favours fluticasone
41Ciclesonide versus other inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Ciclesonide versus fluticasone, Outcome 2 Adverse events: number of patients
with adverse events.
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 2 Ciclesonide versus fluticasone
Outcome: 2 Adverse events: number of patients with adverse events
Study or subgroup Ciclesonide Fluticasone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dose ratio 1:1
Pedersen 2009 101/242 119/250 100.0 % 0.88 [ 0.72, 1.07 ]
Subtotal (95% CI) 242 250 100.0 % 0.88 [ 0.72, 1.07 ]
Total events: 101 (Ciclesonide), 119 (Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Dose ratio 1:2
Pedersen 2009 117/252 119/250 100.0 % 0.98 [ 0.81, 1.17 ]
Subtotal (95% CI) 252 250 100.0 % 0.98 [ 0.81, 1.17 ]
Total events: 117 (Ciclesonide), 119 (Fluticasone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
0.5 0.7 1 1.5 2
Favours ciclesonide Favours fluticasone
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Analysis 2.3. Comparison 2 Ciclesonide versus fluticasone, Outcome 3 Adverse events: 24-hour urine free
cortisol adjusted for creatinine (nmol/mmol).
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 2 Ciclesonide versus fluticasone
Outcome: 3 Adverse events: 24-hour urine free cortisol adjusted for creatinine (nmol/mmol)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Dose ratio 1:1
Pedersen 2009 242 -0.67 (50.7649) 250 -1.21 (7.4003) 100.0 % 0.54 [ -5.92, 7.00 ]
Subtotal (95% CI) 242 250 100.0 % 0.54 [ -5.92, 7.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 Dose ratio 1:2
Pedersen 2009 252 -0.06 (4.6393) 250 -1.21 (7.4003) 100.0 % 1.15 [ 0.07, 2.23 ]
Subtotal (95% CI) 252 250 100.0 % 1.15 [ 0.07, 2.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
-4 -2 0 2 4
Favours ciclesonide Favours fluticasone
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Analysis 2.4. Comparison 2 Ciclesonide versus fluticasone, Outcome 4 Generic FEV1 least square mean (L).
Review: Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
Comparison: 2 Ciclesonide versus fluticasone
Outcome: 4 Generic FEV1 least square mean (L)





N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Dose ratio 1:1
Pedersen 2006 254 257 0 (0.0214) 58.7 % 0.0 [ -0.04, 0.04 ]
Pedersen 2009 239 250 -0.02 (0.0255) 41.3 % -0.02 [ -0.07, 0.03 ]
Subtotal (95% CI) 493 507 100.0 % -0.01 [ -0.04, 0.02 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
2 Dose ratio 1:2
Pedersen 2009 249 250 -0.05 (0.0306) 100.0 % -0.05 [ -0.11, 0.01 ]
Subtotal (95% CI) 249 250 100.0 % -0.05 [ -0.11, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 1.45, df = 1 (P = 0.23), I2 =31%
-0.1 -0.05 0 0.05 0.1
Favours ciclesonide Favours fluticasone
A D D I T I O N A L T A B L E S
Table 1. Characteristics of the interventions
Study ID Ciclesonide dose Comparator ICS Application Inhalation
technique
Treatment period
Ciclesonide versus budesonide Ciclesonide versus
von Berg 2007 160 µg OD (ex-ac-
tuator; equivalent to
200 µg ex-valve) 2 x
80 µg puffs in the
evening
Budesonide 400 µg
OD2 x 200µg puffs
Ciclesonide: HFA-




Not described 12 weeks
Vermeulen 2007 320 µg OD (ex-ac-
tuator; equivalent to
2 puffs of 200 µg











Not described 12 weeks
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Table 1. Characteristics of the interventions (Continued)
tered in the evening , administered in the
evening
Ciclesonide versus fluticasone Ciclesonide versus





Not described 12 weeks




Not described 12 weeks
Pedersen 2006 80 µg BID (ex-ac-
tuator; equivalent to
100 µg BID ex-
valve)
Fluticas-
one 88 µg BID (ex-
actuator dose, equiv-








Pedersen 2009 80 or 160 µg OD
(ex-actuator; equiva-
lent to 100 and 200
µg ex-valve) admin-




100 µg BID ex-








BID: twice daily; ex-actuator: drugs that leaves the inhaler; ex-valve: drugs that leaves the metering chamber valve; HFA-MDI:
hydrofluoroalkane-propelled metered dose inhaler; ICS: inhaled corticosteroid; MDI: metered dose inhaler; OD: once daily.
Table 2. Effect of the intervention: ciclesonide versus budesonide
Dose CIC 160 µg OD versus BUD 400 µg OD CIC 320 µg OD versus BUD 800 µg OD
Dose ratio 1:2 1:2
Study von Berg 2007 Vermeulen 2007
Primary outcomes Primary outcomes
Asthma symptoms: asthma symptom
score (sum score)
ITT: MD 0.01, 95% CI -0.14 to 0.16
PP: MD 0.03, 95% CI -0.20 to 0.25
Non-inferiority acceptance limit = 0.3
Median change from baseline (no CIs re-
ported)
ITT: CIC: -0.07; BUD: -0.14
PP: CIC: -0.07; BUD: -0.14
Asthma symptoms: use of rescue medica-
tion (puff/day)
ITT: MD 0.06 puffs/day, 95% CI -0.26 to
0.38
Not assessed
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Table 2. Effect of the intervention: ciclesonide versus budesonide (Continued)
Asthma symptoms: % of asthma symptom
and rescue medication-free days
ITT: CIC: mean 73%; BUD: mean 70%
No difference between groups
ITTandPP:CIC:median84%;BUD:me-
dian 85%
Lower limit of the between difference was
-1.4% and above non-inferiority limit of -
8%
Exacerbations: patients with exacerba-
tions*
ITT: RR 2.71, 95% CI 0.61 to 12.11;
Analysis 1.1
ITT: RR 1.69, 95% CI 0.36 to 8.00;
Analysis 1.1
Adverse events: patients with adverse
events
Adverse events were reported in 38% of pa-
tients in both groups
ITT: RR** 1.44, 95% CI 0.96 to 2.18
Adverse events: change in body height Mean change from baseline (least square
mean)
CIC: 1.18 cm; BUD: 0.70 cm
Not assessed
Adverse events: 24-hour urine cortisol
adjusted for creatinine
ITT: 2.99 nmol/mmol creatinine; P < 0.
0001, one-sided (decrease greater in the
BUD group)
ITT: significant difference between groups
(lower level in BUD group)
Secondary outcomes Secondary outcomes
Quality of life: PAQLQ(S) ITT: MD -0.11, 95% CI -0.12 to 0.10,
one-sided superiority; Analysis 1.2
Non-inferiority acceptance limits = not
provided
PP not reported
ITT: MD (least square mean) 0.01, 95%
CI -0.14 to 0.16; Analysis 1.2
Non-inferiority acceptance limit = -0.5%
PP results were similar
Quality of life: PACQLQ ITT: MD -0.08, 95% CI -0.27 to 0.11,
one-sided superiority




Compliance Not assessed Not assessed
Lung function: FEV1 (L) ITT: MD (least square means) -0.019 L,
95% CI -0.059 to 0.022; Analysis 1.3
PP: MD (least square means) -0.034 L,
95% CI -75 to 10
Non-inferiority acceptance limit = -100
mL
ITT: MD (least square means) -0.03 L,
95% -0.14 to 0.8; Analysis 1.3
PP:MD (least square means) -0.02 L, 95%
CI -0.13 to 0.1
Non-inferiority acceptance limit = -150
mL
Airway inflammation Not assessed Not assessed
BUD: budesonide; CI: confidence interval; CIC: ciclesonide; ITT: intention to treat analysis; MD: mean difference; OD: once daily;
PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire;
PP: per protocol; RR: risk ratio.
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* Exacerbations were defined as an increasing asthma symptoms requiring change or addition of patient’s medication other than
increasing rescue medication.
** Adverse events that needed treatment, reported in over 2% of patients in CIC or BUD group of safety population (N = 403).
Table 3. Effects of the intervention: ciclesonide versus fluticasone
Dose CIC 80 µg BID vs.
FP 88 µg BID
CIC 160 µg OD vs.
FP 88 µg BID
CIC 80 µg BID vs.
FP 88 µg BID
CIC 160 µg OD vs.
FP 88 µg BID
CIC 80 µg OD vs.
FP 88 µg BID
Dose ratio 1:1 1:1 1:1 1:1 1:2
















Unclear if ITT or
PP *:
0.07, 95% CI -0.14
to 0.28
Non-inferiority ac-
ceptance limit = 0.
30 sum score
Not assessed Asthma symptom
score decreased and






Unclear if ITT or
PP **:
0.07, 95% CI -0.14
to 0.28
Non-inferiority ac-
ceptance limit = 0.
30 sum score
Asthma symptoms:






ITT and PP: 0.00,









PP: CIC: -1.14; FP:
-1.29
All P < 0.0001
Not assessed Use of rescue medi-
cation de-
creased andwas sim-








PP: CIC: -1.21; FP:
-1.29








ITT: -1.01, 95% CI
-4.60 to 2.46
PP: -1.01, 95% CI -
4.82 to 2.51











Not assessed PP: mean percent-
age was high and
did not differ be-
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RR 1.26, 95% CI 0.
34 to 4.66; Analysis
2.1
RR 1.45, 95% CI 0.
47 to 4.49; Analysis
2.1
Not assessed CIC: 2.3%; FP: 2.
2%
RR 3.57, 95% CI 1.
35 to 9.47; Analysis
2.1
Adverse events: %





RR 0.88, 95% CI 0.




events was similar in
both groups
Not assessed RR 0.98, 95% CI 0.
























of CIC was seen in
the restricted ITT
analysis





patients who had re-










95% CI -5.92 to 7.
00; Analysis 2.3
Not assessed Not assessed Safety
analysis**:MD1.15
nmol/mmol, 95%
CI 0.07 to 2.23;
Analysis 2.3
Secondary outcomes
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Table 3. Effects of the intervention: ciclesonide versus fluticasone (Continued)
Quality of life:
PAQLQ
Not assessed ITT and PP:
Non-inferiority was
confirmed CIC 160














Not assessed ITT and PP:
Non-inferiority was
confirmed CIC 160
















































Not assessed Not assessed Not assessed Not assessed Not assessed
BID: twice daily; CI: confidence interval; CIC: ciclesonide; FP: fluticasone; ICS: inhaled corticosteroid; ITT: intention to treat analysis;
OD: once daily; PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life
Questionnaire; PP: per protocol analysis.
* = In this study analyses were based on PP population and analysis of ITT population was used to confirm results, description of the
results are unclear but we assumed it to be based on analysis of PP population.
** = safety analysis excluded patients with concurrent nasal, ophthalmological or dermatological corticosteroid treatment.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search






Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Database search strategies
PubMed search
#11 search #9 and #10
#10 Search (“2007”[Entrez Date] : “2011”[Entrez Date])
#9 Search #5 and #8
#8 Search #6 or #7
#7 Search (((((randomised[Title/Abstract]) OR randomized[Title/Abstract]) OR placebo[Title/Abstract]) OR randomly[Title/Ab-
stract]) OR trial[Title/Abstract]) OR groups[Title/Abstract]
#6 Search “Randomized Controlled Trials”[MESH] OR “Clinical Trials”[MESH] OR “Controlled Clinical Trials”[MESH] OR “Cross-
Over Studies”[MESH] OR “Multicenter Studies”[MESH]
#5 Search #3 and #4
#4 Search ciclesonide[Text Word] OR CIC[Text Word] OR Alvesco[Text Word]
#3 Search #1 or #2
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2. (asthma$ or wheez$).mp.
3. 1 or 2
4. ciclesonide/
5. (ciclesonide or alvesco or CIC).mp.
6. 4 or 5
7. 3 and 6




12. controlled clinical trial/
13. Double Blind Procedure/














28. 25 or 26
29. 28 not 27
30. 24 not 29
31. 7 and 30
32. (2007$ or 2008$ or 2009$ or 2010$ or 2011$).em.
33. 31 and 32
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review is a result of an amendment of a review published in 2009 by Manning assessing the effect of ciclesonide compared to
other ICS in adults and children. In this review we only focused on a population younger than 18 years of age. We based the methods
of this review on the methods of the review of Manning 2009 and apart from the change of population of interest we made some
additional changes. Our primary outcomes were asthma symptoms, exacerbations and adverse effect. We did not include surrogate
measures of lung function as our primary outcome since this is not an outcome that is regarded as relevant to patients, but this outcome
was included as one of our secondary outcomes.
In the earlier review, study quality was assessed using the Jadad scale. We assessed risk of bias using The Cochrane Collaboration’s ’Risk
of bias’ tool. Studies identified in the earlier review were re-assessed. Furthermore, we provide ’Summary of findings’ tables according
to GRADE for primary outcomes.
For the planning of exploring heterogeneity we did not use any cut of points based on values of the I2 statistics, but decisions would
have been based on combined information of I2, Chi2, study characteristics and sample size of individual studies. Additional subgroups
were pre-defined to explore heterogeneity including subgroups according to age (< six years and ≥ six years), asthma severity, dose of
ciclesonide and delivery device (identical or different devices used for ciclesonide and BDP/budesonide/fluticasone) as well as inhalation
manoeuvre.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage; adverse effects]; Androstadienes [administration & dosage; adverse effects];
Anti-Asthmatic Agents [∗administration & dosage; adverse effects]; Asthma [∗drug therapy]; Budesonide [administration & dosage;
adverse effects]; Fluticasone; Pregnenediones [∗administration & dosage; adverse effects]; Randomized Controlled Trials as Topic
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MeSH check words
Adolescent; Child; Child, Preschool; Humans
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